Data di Pubblicazione:
2017
Abstract:
Alemtuzumab is a humanized monoclonal antibody targeting the surface molecule CD52, resulting in a rapid depletion of innate and adaptive immune cells. Infection rates in multiple sclerosis (MS) treatment trials were higher in alemtuzumab than in interferon beta-treated patients. We report two MS patients who developed cytomegalovirus disease within 1 month after the first 5-day cycle of alemtuzumab. Upon identification and appropriate treatment of the infection, each recovered completely. Neurologists should be aware of this serious but treatable complication.
Tipologia CRIS:
03A-Articolo su Rivista
Keywords:
Multiple sclerosis; alemtuzumab; cytomegalovirus; cytomegalovirus reactivation; herpes virus; multiple sclerosis treatment
Elenco autori:
Clerico, Marinella; De Mercanti, Stefania; Artusi, Carlo Alberto; Durelli, Luca; Naismith, Robert T
Link alla scheda completa:
Pubblicato in: